ClinConnect ClinConnect Logo
Search / Trial NCT06654219

Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia

Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER, HOUSTON · Oct 21, 2024

Trial Information

Current as of July 09, 2025

Not yet recruiting

Keywords

Glucagon Like Peptide 1 Receptor (Glp 1 Ra) Full Stomach

ClinConnect Summary

This clinical trial is studying whether switching to a clear liquid diet for 24 hours before undergoing an upper endoscopy can help reduce stomach contents in patients who take a specific type of medication called GLP-1 receptor agonists. The researchers want to find out if this diet can protect against complications during anesthesia, as well as how it affects feelings of thirst, hunger, anxiety, and symptoms like nausea and abdominal pain. They will also be looking at how quickly the stomach empties and whether any side effects occur during the study.

To participate in this trial, you need to be between 65 to 74 years old, be currently taking GLP-1 receptor agonists, and be scheduled for an upper endoscopy. However, there are some reasons you might not be able to join, such as having had certain types of stomach surgery or being pregnant. If you take specific medications for stomach issues or have certain medical conditions, you may also be excluded. Participants will be monitored closely throughout the process, and the study aims to gather important information that could improve patient safety during procedures involving anesthesia.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) agonists
  • Undergoing upper endoscopy only - no colonoscopy due to prep
  • Exclusion Criteria:
  • Previous gastric resection or bypass
  • Gastric band in situ
  • Previous fundoplication
  • Large hiatal hernia
  • Pregnant patients
  • Recent trauma
  • Inability to turn to the right lateral decubitus position.
  • Patients on erythromycin, metoclopramide, domperidone, opioids.
  • Gastroparesis previous

About The University Of Texas Health Science Center, Houston

The University of Texas Health Science Center at Houston (UTHealth) is a leading academic institution dedicated to advancing health through education, research, and clinical practice. As a prominent sponsor of clinical trials, UTHealth leverages its extensive resources and expertise in biomedical research to facilitate innovative studies aimed at improving patient outcomes. The institution is committed to fostering a collaborative environment that promotes scientific discovery and the translation of research findings into effective healthcare solutions, all while adhering to the highest ethical standards and regulatory guidelines. With a multidisciplinary approach, UTHealth plays a critical role in addressing complex health challenges and enhancing the quality of life in diverse communities.

Locations

Houston, Texas, United States

Houston, Texas, United States

Patients applied

0 patients applied

Trial Officials

Sudipta Sen, MD, FASA

Principal Investigator

The University of Texas Health Science Center, Houston

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported